Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GLIMEPIRIDE Cause Dermatitis exfoliative? 28 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Dermatitis exfoliative have been filed in association with GLIMEPIRIDE (Glimepiride). This represents 0.5% of all adverse event reports for GLIMEPIRIDE.

28
Reports of Dermatitis exfoliative with GLIMEPIRIDE
0.5%
of all GLIMEPIRIDE reports
28
Deaths
28
Hospitalizations

How Dangerous Is Dermatitis exfoliative From GLIMEPIRIDE?

Of the 28 reports, 28 (100.0%) resulted in death, 28 (100.0%) required hospitalization, and 26 (92.9%) were considered life-threatening.

Is Dermatitis exfoliative Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GLIMEPIRIDE. However, 28 reports have been filed with the FAERS database.

What Other Side Effects Does GLIMEPIRIDE Cause?

Hypoglycaemia (1,403) Blood glucose increased (446) Acute kidney injury (339) Drug ineffective (339) Diarrhoea (257) Blood glucose decreased (232) Lactic acidosis (219) Glycosylated haemoglobin increased (214) Diabetes mellitus inadequate control (213) Hypoglycaemic coma (187)

What Other Drugs Cause Dermatitis exfoliative?

CIPROFLOXACIN (91) ALLOPURINOL (86) SULFAMETHOXAZOLE\TRIMETHOPRIM (75) CLOPIDOGREL BISULFATE (73) FUROSEMIDE (73) ATORVASTATIN (71) AMLODIPINE (70) ACETAMINOPHEN (66) VANCOMYCIN (66) SIMVASTATIN (64)

Which GLIMEPIRIDE Alternatives Have Lower Dermatitis exfoliative Risk?

GLIMEPIRIDE vs GLIMEPIRIDE\ROSIGLITAZONE GLIMEPIRIDE vs GLIPIZIDE GLIMEPIRIDE vs GLIVEC GLIMEPIRIDE vs GLOFITAMAB GLIMEPIRIDE vs GLOFITAMAB-GXBM

Related Pages

GLIMEPIRIDE Full Profile All Dermatitis exfoliative Reports All Drugs Causing Dermatitis exfoliative GLIMEPIRIDE Demographics